Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
Holding DNLI?
Track your performance easily
DNLI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.56 - $32.13
Previous Close$29.6
Volume885.92K
Average Volume (3M)831.91K
Market Cap
$4.26B
Enterprise Value$3.41B
Total Cash (Recent Filing)$896.04M
Total Debt (Recent Filing)$48.75M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Mar 03, 2025EPS Estimate
-$0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding143,921,624
10 Day Avg. Volume802,879
30 Day Avg. Volume831,909
Standard Deviation0.18
R-Squared0.17
Alpha0.00695
Financial Highlights & Ratios
Price to Book (P/B)3.06
Price to Sales (P/S)3339.02
Price to Cash Flow (P/CF)-11.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.36
Enterprise Value/Gross Profit10.33
Enterprise Value/Ebitda-19.84
Forecast
1Y Price Target
$40.18Price Target Upside35.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Denali Therapeutics News
PremiumCompany Announcements
Denali Therapeutics’ Oditrasertib Phase 2 Study Discontinued
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyDNL310 demonstrated a 90% mean reduction in cerebrospinal fluid heparan sulfate from baseline, with sustained effects through Week 104, showcasing its strong potential in treating MPS II.
Regulatory ProgressDenali Therapeutics reached an agreement with the FDA for an accelerated approval path for DNL310, which is expected to significantly expedite the launch timeline for this promising treatment.
Safety And Biomarker DataRobust long-term safety and biomarker data supporting encouraging behavioral and cognitive improvements in treated patients further solidify the case for accelerated approval of DNL310.
Bears Say
Collaboration TerminationBiogen terminated its license to the ATV:Abeta program.
CompetitionRARE is a competitor with a pivotal study ongoing for AAV gene therapy for Sanfilippo.
Price Target ReductionThe price target has been reduced from $95 to $90.
---
Ownership Overview
9.12% Insiders
31.05% Mutual Funds
9.83% Other Institutional Investors
35.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $14.56 and its highest was $32.13 in the past 12 months.
What is Denali Therapeutics’s market cap?
Currently, no data Available
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 115 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.595 by -$0.035.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -$0.78.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 143,921,630 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.595. Following the earnings report the stock price went up 0.169%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Among the largest hedge funds holding Denali Therapeutics’s share is Baker Bros Advisors LP. It holds Denali Therapeutics’s shares valued at 87M.
---
Denali Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.18 (35.74% Upside)
$40.18 (35.74% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $317.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.42%
12-Months-Change
Fundamentals
Return on Equity
-35.09%
Trailing 12-Months
Asset Growth
17.56%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
---
DNLI Stock 12 Month Forecast
Average Price Target
$40.18
▲(35.74% Upside)
Technical Analysis
Best Analysts Covering DNLI
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+35.51%
reiterated a buy rating 2 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +35.51% per trade.
---